Literature DB >> 2066972

Computer simulation of the binding of saframycin A to d (GATGCATC)2.

G C Hill1, W A Remers.   

Abstract

The binding of Saframycin A to the octanucleotide duplex d(GATGCATC)2 was investigated using molecular dynamics. For covalent binding at N2 of the central guanine, only the R configuration at the alkylating carbon (C7) was permitted for B DNA and the 3' direction in the minor groove was preferred by 50.6 kcal/mol. The dihydroquinone form of saframycin A gave stronger binding than the quinone, in agreement with the literature. Addition of solvent and counterions made no significant change in the geometry model. The proposed mechanism of DNA alkylation, involving iminium ion intermediates from the dihydroquinone or quinone, was investigated by modeling these species. They gave models with good net binding enthalpies, and C7 was in close proximity to N2 of guanine. The noncovalent binding of saframycin A and its dihydroquinone in the vicinity of guanine also was favorable in the 3' direction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2066972     DOI: 10.1021/jm00111a011

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Antitumor activity of tetrahydroisoquinoline analogues 3-epi-jorumycin and 3-epi-renieramycin G.

Authors:  Jonathan W Lane; Alberto Estevez; Kyle Mortara; Ondine Callan; Jeffrey R Spencer; Robert M Williams
Journal:  Bioorg Med Chem Lett       Date:  2006-05-02       Impact factor: 2.823

2.  Identification of GAPDH as a protein target of the saframycin antiproliferative agents.

Authors:  Chengguo Xing; Jacob R LaPorte; Joseph K Barbay; Andrew G Myers
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

Review 3.  Biosynthesis of DNA-Alkylating Antitumor Natural Products.

Authors:  Qiu-Yue Nie; Yu Hu; Xian-Feng Hou; Gong-Li Tang
Journal:  Molecules       Date:  2022-09-27       Impact factor: 4.927

4.  Synergistic Cytotoxicity of Renieramycin M and Doxorubicin in MCF-7 Breast Cancer Cells.

Authors:  Jortan O Tun; Lilibeth A Salvador-Reyes; Michael C Velarde; Naoki Saito; Khanit Suwanborirux; Gisela P Concepcion
Journal:  Mar Drugs       Date:  2019-09-16       Impact factor: 5.118

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.